Avalyn Pharma Q2 FY26 net loss widens to $28.94 million
AVLN•Cash position and clinical program updates
Cash, cash equivalents, and marketable securities totaled USD 413.5 million at June 30, 2026; runway is projected into 2029.
MIST Phase 2b enrollment for AP01 reached 398 patients; topline data is expected in the second half of 2027, and the AURA AP02 readout is seen late 2027.
Q2 loss widens as research spending increases
Avalyn Pharma posted a GAAP net loss of USD 28.9 million in Q2 2026, widening from USD 20.2 million a year earlier.
R&D expense climbed to USD 24.7 million from USD 17.9 million, driven by AP01 and AP02 trials plus the SAIL extension study.
G&A expense rose to USD 6.6 million from USD 3.9 million on higher headcount and personnel costs, including stock-based compensation.
